Masahiro Miura1, Takuya Iwasaki, Hiroshi Goto. 1. From the *Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Ibaraki, Japan; and †Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
Abstract
PURPOSE: The purpose of this study was to report a case of macular hole formation in a patient with myopic choroidal neovascularization (CNV), who was administered intravitreal bevacizumab. METHODS: A 55-year-old woman with high myopia presented with a sudden decrease in vision in her right eye. Optical coherence tomography imaging showed subfoveal type 2 CNV and a preretinal structure with vitreomacular traction. The patient received intravitreal bevacizumab treatment for the CNV. RESULTS: Four weeks after the second intravitreal bevacizumab injection, regression of CNV and formation of a macular hole were confirmed from the findings of the optical coherence tomography image. The patient was followed up without further treatment. Six months after the second intravitreal bevacizumab injection, the macular hole closed spontaneously, and visual acuity improved in her right eye. CONCLUSION: Intravitreal bevacizumab is a powerful modality in the management of myopic CNV; however, the possibility of infrequent complication should be considered.
PURPOSE: The purpose of this study was to report a case of macular hole formation in a patient with myopic choroidal neovascularization (CNV), who was administered intravitreal bevacizumab. METHODS: A 55-year-old woman with high myopia presented with a sudden decrease in vision in her right eye. Optical coherence tomography imaging showed subfoveal type 2 CNV and a preretinal structure with vitreomacular traction. The patient received intravitreal bevacizumab treatment for the CNV. RESULTS: Four weeks after the second intravitreal bevacizumab injection, regression of CNV and formation of a macular hole were confirmed from the findings of the optical coherence tomography image. The patient was followed up without further treatment. Six months after the second intravitreal bevacizumab injection, the macular hole closed spontaneously, and visual acuity improved in her right eye. CONCLUSION: Intravitreal bevacizumab is a powerful modality in the management of myopic CNV; however, the possibility of infrequent complication should be considered.